DanCann Pharma A/S intends to initiate and complete a partly secured rights issue of up to DKK 18.5 million to restructure, strengthen and secure a debt-free capital structure
COPENHAGEN, Denmark, 29 March 2024 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, intends to resolve on a new issue of shares with pre-emptive subscription rights for the Company's existing shareholders of up to approx. DKK 18.5 million before transaction costs (the "Rights Issue"). The Company will call for an extraordinary general meeting to be held (the “EGM”) with a proposal to reduce the share capital of the Company and proposals to provide the necessary authorisations to the board of directors to resolve on the Rights